Table 1.
Clinical trials of CAR-NK cells in hematological malignancies.
| No. | Target | Conditions | NK cell sources | Status | Phase | NCT |
|---|---|---|---|---|---|---|
| 1 | CD19 | B-cell malignancies | UCB | recruiting | phase I | NCT04796675 |
| 2 | CD19 | B-cell NHL | unknown | not yet recruiting | early phase I | NCT04639739 |
| 3 | CD19 | B-cell lymphoma | iPSCs (FT596) | recruiting | phase I | NCT04555811 |
| 4 | CD19 | B-cell malignancies | iPSCs (FT596) | recruiting | Phase I | NCT04245722 |
| 5 | CD19 | B-cell NHL | iPSCs | not yet recruiting | early phase 1 | NCT03824951 |
| 6 | CD19 | B-Cell lymphoma | unknown | not yet recruiting | early phase I | NCT03690310 |
| 7 | CD19 | B-cell malignancies | UCB | completed | phase I/II | NCT03056339 ref (31). |
| 8 | CD19 | B-cell malignancies | NK-92 cells | unknown | phase I/II | NCT02892695 |
| 9 | CD19 | B-cell ALL | PBMCs | completed | phase I | NCT00995137 |
| 10 | CD22 | Refractory B-Cell Lymphoma | unknown | not yet recruiting | early phase I | NCT03692767 |
| 11 | CD19/CD22 | Refractory B-Cell Lymphoma | unknown | not yet recruiting | early phase I | NCT03824964 |
| 12 | CD7 | T-cell malignancies, AML | NK-92 cells | recruiting | phase I/II | NCT02742727 |
| 13 | CD33 | AML | NK-92 cells | completed | phase I/II | NCT02944162 ref (74). |
| 14 | NKG2D Ligands | AML, MDS | PBMC | recruiting | phase I | NCT04623944 |
| 15 | BCMA | MM | NK-92 cells | recruiting | phase I/II | NCT03940833 |